ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

0QNV Addex Therapeutics Ltd

3.02
0.00 (0.00%)
Última actualización: 19:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Addex Therapeutics Ltd 0QNV London Acción Ordinaria
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 3.02 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.02
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202400:00UKREGAddex Provides Update on ADX71149 Phase 2 Epilepsy Study
19/4/202400:00UKREGAddex to Present at the Swiss Biotech Day 2024
18/4/202400:00UKREGAddex Therapeutics Reports Full Year 2023 Financial Results..
11/4/202400:00UKREGAddex Therapeutics to Release Full-Year 2023 Financial..
03/4/202400:00UKREGAddex and Perceptive Launch Neurosterix with $63 Million to..
14/3/202401:00UKREGAddex to Present at the Bio-Europe Spring 2024 Conference
31/1/202400:00UKREGAddex Enters into At-The-Market ADS Offering Agreement with..
09/1/202400:00GLOBEAddex to Present at the Swiss Equities Baader Conference
05/1/202400:30GLOBEAddex to Present at Biotech Showcase™ 2024
20/12/202300:00GLOBEAddex Shareholders Approve All Resolutions at Extraordinary..
14/12/202300:00GLOBEAddex Creates Treasury Shares
29/11/202300:00GLOBEAddex Reports Q3 2023 Financial Results and Provides..
28/11/202300:00GLOBEAddex Convenes Extraordinary General Meeting
23/11/202300:00GLOBEAddex Therapeutics to Release Third Quarter 2023 Financial..
14/11/202300:00GLOBEAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment..
08/11/202300:00GLOBEAddex Regains Nasdaq Listing Compliance
02/11/202301:00GLOBEAddex Announces Participation in the Bio-Europe 2023..
20/10/202300:00GLOBEAddex Completes ADS Ratio Change
06/10/202315:00GLOBEAddex Announces Plan to Implement ADS Ratio Change
20/9/202300:00GLOBEAddex mGlu2 NAM Cognition Program Receives €4 Million Grant
06/9/202300:00GLOBEAddex Announces Participation in the H.C. Wainwright 25th..
05/9/202300:00GLOBEAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout..
04/9/202300:00GLOBEAddex’s Dipraglurant Development in Post-Stroke Recovery..
10/8/202300:00GLOBEAddex Reports 2023 Half Year and Second Quarter Financial..
04/8/202300:00GLOBEAddex Therapeutics to Release Half-Year 2023 Financial..
03/8/202300:00GLOBEAddex GABAB Positive Allosteric Modulator Program to Receive..
24/7/202300:00GLOBEAddex mGlu2PAM Demonstrates Potential in Substance Use..
15/6/202300:00GLOBEAddex Increases Issued Share Capital to Create Treasury..
01/6/202300:00GLOBEAddex Shareholders Approve All Resolutions at Annual General..
18/5/202300:00GLOBEAddex Receives Nasdaq Notification Regarding Minimum Bid..
11/5/202300:00GLOBEAddex Reports Q1 2023 Financial Results and Provides..
10/5/202300:00GLOBEAddex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s..
05/5/202300:00GLOBEAddex Convenes Annual General Meeting 2023
04/5/202300:00GLOBEAddex Therapeutics to Release Q1 2023 Financial Results and..

Su Consulta Reciente

Delayed Upgrade Clock